Oslo, 31 October 2024 – In the third quarter of 2024, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies, delivered revenues of NOK 123.1 million compared to 141.0 in the corresponding quarter last year. Adjusted EBITDA amounted to NOK 8.6 million compared to NOK 17.4 million in 2023. Gross margin ended at 37.1 per...